TVRD · CIK 0001346830 · operating
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral, small molecule therapies that target STAT3 to treat fibrosis-driven diseases. The company's therapeutic approach focuses on conditions with significant unmet medical needs in the United States. The company was incorporated in Delaware and founded in 2017, with headquarters in Sugar Land, Texas.
The company's lead product candidate, TTI-101, is in Phase 2 clinical development for fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). A second product candidate, TTI-109, an oral small molecule STAT3 inhibitor, remains in preclinical development.
Tvardi operates as a pre-revenue clinical-stage entity with a small operational footprint of 12 full-time employees. As a development-stage company, the organization has not yet generated meaningful revenue and remains dependent on capital resources to fund ongoing research and clinical development activities.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-15.53 | $-15.53 | -609.1% | |
| 2023 | $-2.19 | $-2.19 | -37.7% | |
| 2022 | $-1.59 | $-1.59 | +8.6% | |
| 2021 | $-1.74 | $-1.74 | -209.4% | |
| 2020 | $1.59 | $1.60 | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | $-0.49 | $-0.49 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-11 | 0001558370-25-002705 | SEC ↗ |
| 2023-12-31 | 2024-03-06 | 0001558370-24-002609 | SEC ↗ |
| 2022-12-31 | 2023-03-06 | 0001558370-23-002913 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001558370-22-002555 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001558370-21-001839 | SEC ↗ |
| 2019-12-31 | 2020-02-27 | 0001558370-20-001659 | SEC ↗ |
| 2018-12-31 | 2019-03-12 | 0001564590-19-007389 | SEC ↗ |
| 2017-12-31 | 2018-03-15 | 0001564590-18-005879 | SEC ↗ |
| 2016-12-31 | 2017-03-10 | 0001193125-17-077107 | SEC ↗ |
| 2015-12-31 | 2016-03-11 | 0001193125-16-500345 | SEC ↗ |
| 2014-12-31 | 2015-03-27 | 0001193125-15-107249 | SEC ↗ |
| 2013-12-31 | 2014-03-28 | 0001193125-14-119005 | SEC ↗ |